@article{6831e4fb198647deab04b994327b9d1c,
title = "Distinct roles of interferon alpha and beta in controlling chikungunya virus replication and modulating neutrophil-mediated inflammation",
abstract = "Type I interferons (IFNs) are key mediators of the innate immune response. Although members of this family of cytokines signal through a single shared receptor, biochemical and functional variation exists in response to different IFN subtypes. While previous work has demonstrated that type I IFNs are essential to control infection by chikungunya virus (CHIKV), a globally emerging alphavirus, the contributions of individual IFN subtypes remain undefined. To address this question, we evaluated CHIKV pathogenesis in mice lacking IFN-β (IFN-β knockout [IFN-β-KO] mice or mice treated with an IFN-β-blocking antibody) or IFN-α (IFN regulatory factor 7 knockout [IRF7-KO] mice or mice treated with a pan-IFN-α-blocking antibody). Mice lacking either IFN-α or IFN-β developed severe clinical disease following infection with CHIKV, with a marked increase in foot swelling compared to wild-type mice. Virological analysis revealed that mice lacking IFN-α sustained elevated infection in the infected ankle and in distant tissues. In contrast, IFN-β-KO mice displayed minimal differences in viral burdens within the ankle or at distal sites and instead had an altered cellular immune response. Mice lacking IFN-β had increased neutrophil infiltration into musculoskeletal tissues, and depletion of neutrophils in IFN-β-KO but not IRF7-KO mice mitigated musculoskeletal disease caused by CHIKV. Our findings suggest disparate roles for the IFN subtypes during CHIKV infection, with IFN-β limiting early viral replication and dissemination and IFN-β modulating neutrophil-mediated inflammation. IMPORTANCE Type I interferons (IFNs) possess a range of biological activity and protect against a number of viruses, including alphaviruses. Despite signaling through a shared receptor, there are established biochemical and functional differences among the IFN subtypes. The significance of our research is in demonstrating that IFN-β and IFN-β both have protective roles during acute chikungunya virus (CHIKV) infection but do so by distinct mechanisms. IFN-β limits CHIKV replication and dissemination, whereas IFN-β protects from CHIKV pathogenesis by limiting inflammation mediated by neutrophils. Our findings support the premise that the IFN subtypes have distinct biological activities in the antiviral response.",
keywords = "Chikungunya virus, Host-pathogen interactions, Innate immunity, Interferons",
author = "Cook, {Lindsey E.} and Locke, {Marissa C.} and Young, {Alissa R.} and Kristen Monte and Hedberg, {Matthew L.} and Shimak, {Raeann M.} and Sheehan, {Kathleen C.F.} and Veis, {Deborah J.} and Diamond, {Michael S.} and Lenschow, {Deborah J.}",
note = "Funding Information: We thank the Washington University Musculoskeletal Research Center for performing paraffin embedding and sectioning and the H&E staining used for these studies. We also acknowledge that microscopy imaging was performed in part through the use of the Washington University Center for Cellular Imaging (WUCCI). We also thank Robert D. Schreiber (Washington University School of Medicine) for his helpful discussion and assistance with the IFN-α-and IFN-β-blocking antibodies. L.E.C. was supported by a National Institutes of Health (NIH) postdoctoral research training grant (T32 CA009547) (https://www.nih.gov/). A.R.Y. was supported by a National Institute of General Medical Sciences Cellular, Biochemical, and Molecular (CMB) Sciences predoctoral research training grant (T32 GM007067) (https://www.nigms.nih .gov/). D.J.V. was supported by the NIH (R01 AR070030 and R21 AR073507) (https:// www.nih.gov/) and Shriners Hospitals for Children—St. Louis (85117) (https://www .shrinershospitalsforchildren.org/st-louis). M.S.D. was supported by the NIH (R01 AI143673, R01 AI127513, and R01 AI123348) (https://www.nih.gov/). D.J.L. was supported by the NIH (R01 AI127513 and R21 AI135490) (https://www.nih.gov/). The Washington University Musculoskeletal Research Center received funding from the NIH (P30 AR057235) (https://www.nih.gov/). The Washington University Center for Cellular Imaging was supported by the Washington University School of Medicine, The Children{\textquoteright}s Discovery Institute of Washington University, and St. Louis Children{\textquoteright}s Hospital (CDI-CORE-2015-505) (http://www.childrensdiscovery.org/grants) and by the Foundation for Barnes-Jewish Hospital (3770) (https://www.foundationbarnesjewish.org/ Grants). Funding for this project was provided in part by the Washington University Rheumatic Diseases Research Resource-Based Center funded by the NIH (P30 AR073752) (https://www.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We declare the following conflict of interest: M.S.D. is a consultant for Inbios and Atreca and is on the scientific advisory board of Moderna. Publisher Copyright: {\textcopyright} 2019 American Society for Microbiology.",
year = "2020",
month = jan,
day = "1",
doi = "10.1128/JVI.00841-19",
language = "English",
volume = "94",
journal = "Journal of Virology",
issn = "0022-538X",
number = "1",
}